This illustration provided by AstraZeneca depicts packaging for their medication Beyfortus. U.S. officials have approved a new long-acting drug to protect babies and toddlers against a respiratory virus that causes thousands of hospitalizations each year. The Food and Drug Administration on Monday, July 17, 2023 approved the injection for infants and children up to 2 years old. (AstraZeneca via AP)
By Matthew Perrone
U.S. officials on Monday approved the first long-acting drug to protect babies and toddlers against a respiratory virus that sends tens of thousands of American children to the hospital each year.
RSV is a cold-like nuisance for most healthy people, but it can be life-threatening in the very young and the elderly.
The Food and Drug Administration approved the injection for infants and children up to 2 years old who face increased risk of severe RSV.
“Today’s approval addresses the great need for products to help reduce the impact of RSV disease on children, families and the health care system” said FDA's Dr. John Farley in a statement.
Last year, a surge in RSV cases flooded U.S. hospitals with wheezing children. There are no vaccines for babies yet, though Pfizer and other companies are working on them.
AstraZeneca’s drug, to be sold under the brand name Beyfortus, is a laboratory-made version of an antibody that helps the immune system fight off RSV. Under the FDA approval, babies — including preterm infants — can receive a single injection to protect against their first season of RSV, which typically lasts about five months. Children up to age 2 can receive another dose to protect them during their second season facing the virus.
Beyfortus, which will be marketed in the U.S. by Sanofi, is already approved in Canada, Europe and the U.K. Sanofi did not immediately announce the U.S. price of the treatment.
FDA officials approved the drug based on three studies showing Beyfortus reduced the risk of RSV infection between 70% and 75% among infants and children 2 and younger.
Advisers to the Centers for Disease Control and Prevention will meet early next month to recommend exactly who should get the drug.
A similar antibody drug won FDA approval more than 20 years ago, but it’s only recommended for high-risk babies and requires monthly injections. Pediatricians say the drug is underutilized and they expect the longer-lasting effect of AstraZeneca's shot to improve uptake.
In the U.S., about 58,000 children younger than 5 are hospitalized for RSV each year and several hundred die.
After decades of setbacks for RSV research, drugmakers have made big strides this year, launching the first vaccines against the virus. In May, the FDA approved two RSV vaccines for older adults from GlaxoSmithKline and Pfizer. In August, the FDA is expected to make a decision on approving Pfizer’s vaccine for pregnant women, with the aim of passing along protection to their newborns.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
Adam Mosseri, head of Instagram, faced withering questions on Capitol Hill about the reports the social media app was aware of the severe mental health impacts it was having on teenage girls. Karen Kornbluh, the director of digital innovation and democracy for the German Marshall Fund, joined Cheddar to discuss the rare show of bipartisan outrage on display at the Senate hearing. "The senators came really loaded for bear on both sides of the aisle," she said. Kornbluh explained how senators like Richard Blumenthal (D-Conn.) set up fake Instagram accounts with teen girl profiles in order to research the effects firsthand.
Back in 2010, several large companies pledged to work towards stopping deforestation by 2020. Companies like Nestle and Carrefour even went further to say that they would eliminate deforestation from their supply chains altogether. However, fast forward to 2020, many of these companies have failed to reach that goal. Associate Director of Forest at the CDP Nadia Bishai, joined Cheddar to discuss more.
A new study by Pfizer-BioNTech found that a third dose of their COVID-19 vaccine is effective against the emerging omicron variant. The pharmaceutical giants also look to manufacture a vaccine specific to the omicron variant by March 2022.
Heila Technologies, a startup that develops hardware and software to integrate renewables and batteries on a microgrid, is helping to power the first clean energy microgrid for Auto Mercado, a top supermarket chain in Costa Rica. The plant will reduce 20 tons of CO2 emissions per year. Heila Technologies CEO Francisco Morocz joins Cheddar Climate to discuss.
The U.S. has a million-ton problem: each year, hundreds of pounds of plastic waste are produced per person, and that leads to close to 2 million tons of that waste leaking into the environment. Eight million tons end up in the ocean, where it hinders marine life, damages ecosystems, and impacts industry. But in recent years, Congress has introduced measures including the Save our Seas act to try to mitigate the issue and turn our plastic problem around. Sen. Chris Murphy (D-CT) joins Cheddar Climate to discuss why the U.S. is the top global polluter of plastic, what Congress is doing to try to fix the issue, and more.
Daniel Huppmann, researcher at International Institute for Applied Systems Analysis, joins Cheddar Climate, where he explains how the global economy could be 2% bigger by 2100 if the world can hold global warming below 1.5°C.
While the World Health Organization strongly advises against a COVID-19 vaccine mandate, national and local governments are moving to make inoculations compulsory. Cheddar News speaks with Dr. Joel Zinberg of the Competitive Enterprise Institute on the issue.
